Screener
CURE vs LABU
Direxion Daily Healthcare Bull 3X Shares vs Direxion Daily S&P Biotech Bull 3X Shares
Key differences
- LABU is significantly larger than CURE — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, LABU has delivered higher annualized returns.
Side-by-side comparison
| CURE | LABU | |
|---|---|---|
| Annual cost (TER) | 0.94% | 0.96% |
| Fund size (AUM) | $138M | $528M |
| Since | 2011 | 2015 |
| Dividend yield | 1.33% | 0.69% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | leveraged | leveraged |
| CAGR 1Y | +31.7% | +246.3% |
| CAGR 3Y | +0.8% | +10.2% |
| CAGR 5Y | +0.7% | -32.0% |
| Sharpe 3Y | 0.14 | 0.48 |
| Volatility 1Y | 42.92% | 75.02% |
| Max drawdown | -69.19% | -98.96% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to CURE and LABU
Explore further